Shanxi Zhendong Pharmaceutical (300158) — Tangible Net Worth Ratio
Shanxi Zhendong Pharmaceutical (300158) has a Tangible Net Worth Ratio of 88.8% as of September 2025. This metric is calculated by deducting intangible assets (CN¥407.29 Million) from net assets (CN¥3.63 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shanxi Zhendong Pharmaceutical short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanxi Zhendong Pharmaceutical Tangible Net Worth Ratio (2007–2024)
This chart shows how Shanxi Zhendong Pharmaceutical's Tangible Net Worth Ratio has changed across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 88.8%, reflecting net assets of CN¥3.63 Billion with intangible assets of CN¥407.29 Million CNY. See defensive interval ratio of Shanxi Zhendong Pharmaceutical to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanxi Zhendong Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Shanxi Zhendong Pharmaceutical (300158) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 89.8% | CN¥3.66 Billion | CN¥371.90 Million | CN¥4.98 Billion | ▼ -1.3 pp |
| 2023 | 91.2% | CN¥5.14 Billion | CN¥454.50 Million | CN¥6.18 Billion | ▼ -0.2 pp |
| 2022 | 91.4% | CN¥5.22 Billion | CN¥451.18 Million | CN¥6.55 Billion | ▼ -3.2 pp |
| 2021 | 94.5% | CN¥8.05 Billion | CN¥439.60 Million | CN¥10.09 Billion | ▲ +1.0 pp |
| 2020 | 93.6% | CN¥5.63 Billion | CN¥362.53 Million | CN¥7.60 Billion | ▲ +1.0 pp |
| 2019 | 92.5% | CN¥5.44 Billion | CN¥405.86 Million | CN¥6.92 Billion | ▼ -0.1 pp |
| 2018 | 92.7% | CN¥5.36 Billion | CN¥392.70 Million | CN¥7.21 Billion | ▼ -0.4 pp |
| 2017 | 93.0% | CN¥5.56 Billion | CN¥386.74 Million | CN¥7.61 Billion | ▲ +0.1 pp |
| 2016 | 92.9% | CN¥5.27 Billion | CN¥371.80 Million | CN¥6.87 Billion | ▲ +9.5 pp |
| 2015 | 83.5% | CN¥2.03 Billion | CN¥335.78 Million | CN¥4.07 Billion | ▼ -1.1 pp |
| 2014 | 84.5% | CN¥1.97 Billion | CN¥304.79 Million | CN¥2.86 Billion | ▼ -0.5 pp |
| 2013 | 85.1% | CN¥1.96 Billion | CN¥292.42 Million | CN¥2.80 Billion | ▼ -2.1 pp |
| 2012 | 87.2% | CN¥1.90 Billion | CN¥243.21 Million | CN¥2.58 Billion | ▼ -5.0 pp |
| 2011 | 92.2% | CN¥1.86 Billion | CN¥145.04 Million | CN¥2.26 Billion | ▼ -6.0 pp |
| 2010 | 98.2% | CN¥1.78 Billion | CN¥32.16 Million | CN¥2.17 Billion | ▲ +6.9 pp |
| 2009 | 91.3% | CN¥359.31 Million | CN¥31.43 Million | CN¥643.18 Million | ▲ +1.0 pp |
| 2008 | 90.2% | CN¥266.72 Million | CN¥26.02 Million | CN¥496.69 Million | ▲ +2.6 pp |
| 2007 | 87.7% | CN¥176.42 Million | CN¥21.79 Million | CN¥466.70 Million | — |